Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

Space: StayCurrentMD Author: Erin G. Brown, E. Stanton Adkins, Peter Mattei, Fredric A. Hoffer, Sandra L. Wootton-Gorges, Wendy B. London, Arlene Naranjo, Mary L. Schmidt, Michael D. Hogarty, Meredith S. Irwin, Susan L. Cohn, Julie R. Park, John M. Maris, Rochelle Bagatell, Clare J. Published:

Author / Expert

Erin G. Brown, E. Stanton Adkins, Peter Mattei, Fredric A. Hoffer, Sandra L. Wootton-Gorges, Wendy B. London, Arlene Naranjo, Mary L. Schmidt, Michael D. Hogarty, Meredith S. Irwin, Susan L. Cohn, Julie R. Park, John M. Maris, Rochelle Bagatell, Clare J.

Topic overview

The International Neuroblastoma Risk Group (INRG) classifier utilizes a staging system based on pretreatment imaging criteria in which image-defined risk factors (IDRFs) are used to evaluate the extent of locoregional disease. Children's Oncology Group (COG) study ANBL0531 prospectively examined institutional determination of IDRF status and compared that to a standardized central review.

Keywords

Hashtags

0 Views
0 Comments

Comments

Loading comments...